Combinatorial immunotherapy

PD-L1 blockade engages tumor-infiltrating lymphocytes to co-express targetable activating and inhibitory receptors
Guillaume Beyrend, Esmé van der Gracht, Ayse Yilmaz, Suzanne van Duikeren, Marcel Camps, Thomas Höllt, Anna Vilanova, Vincent van Unen, Frits Koning, Noel F. C. C. de Miranda, Ramon Arens, Ferry Ossendorp

Journal for ImmunoTherapy of Cancer Dec 2019, 7 (1) 217; DOI: 10.1186/s40425-019-0700-3
Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8⁺ T cells directly within the tumor microenvironment
Stefani Spranger, Holly K Koblish, Brendan Horton, Peggy A Scherle, Robert Newton, Thomas F Gajewski

Journal for ImmunoTherapy of Cancer Dec 2014, 2 (1) 3; DOI: 10.1186/2051-1426-2-3
Therapeutic efficacy of combined blockade of CTLA-4 +/- PD-L1 +/- IDO is associated with re-activation of T cells directly within the tumor microenvironment
Stefani Spranger, Thomas Gajewski

Journal for ImmunoTherapy of Cancer Nov 2013, 1 (Suppl 1) O8; DOI: 10.1186/2051-1426-1-S1-O8

Main menu